Credit Suisse’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-75,752
| Closed | -$1.34M | – | 4082 |
|
|
2018
Q3 | $1.34M | Buy |
75,752
+22,848
| +43% | +$392K | ﹤0.01% | 2645 |
|
|
2018
Q2 | $729K | Buy |
+52,904
| New | +$628K | ﹤0.01% | 3235 |
|
|
2017
Q1 | – | Sell |
-15,265
| Closed | -$39K | – | 4212 |
|
|
2016
Q4 | $39K | Sell |
15,265
-5,915
| -28% | -$17K | ﹤0.01% | 4038 |
|
|
2016
Q3 | $66K | Sell |
21,180
-5,128
| -19% | -$16K | ﹤0.01% | 3988 |
|
|
2016
Q2 | $84K | Buy |
26,308
+1,826
| +7% | +$6.69K | ﹤0.01% | 4088 |
|
|
2016
Q1 | $77K | Sell |
24,482
-14,910
| -38% | -$48.7K | ﹤0.01% | 3859 |
|
|
2015
Q4 | $158K | Buy |
39,392
+26,252
| +200% | +$121K | ﹤0.01% | 3977 |
|
|
2015
Q3 | $60K | Sell |
13,140
-57,344
| -81% | -$300K | ﹤0.01% | 4160 |
|
|
2015
Q2 | $366K | Sell |
70,484
-723
| -1% | -$4.34K | ﹤0.01% | 3911 |
|
|
2015
Q1 | $446K | Sell |
71,207
-15,014
| -17% | -$86.7K | ﹤0.01% | 3623 |
|
|
2014
Q4 | $542K | Buy |
86,221
+28,156
| +48% | +$172K | ﹤0.01% | 3652 |
|
|
2014
Q3 | $353K | Buy |
58,065
+19,494
| +51% | +$133K | ﹤0.01% | 3849 |
|
|
2014
Q2 | $254K | Sell |
38,571
-154,061
| -80% | -$1.74M | ﹤0.01% | 4210 |
|
|
2014
Q1 | $4.59M | Buy |
192,632
+95,858
| +99% | +$1.39M | ﹤0.01% | 1840 |
|
|
2013
Q4 | $1.03M | Buy |
96,774
+21,289
| +28% | +$235K | ﹤0.01% | 3252 |
|
|
2013
Q3 | $1.01M | Buy |
75,485
+13,717
| +22% | +$217K | ﹤0.01% | 2959 |
|
|
2013
Q2 | $811K | Buy |
+61,768
| New | +$833K | ﹤0.01% | 2958 |
|
Other funds holding ECYT
Credit Suisse's ECYT Position: Q4 2018 in Review
Credit Suisse sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 75,752 shares — an estimated $1.34M sold.
Credit Suisse first reported a position in ECYT in Q2 2013 and held it in 17 quarters. The position peaked at $4.59M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Credit Suisse reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Credit Suisse sold 75,752 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $1.34M.
- Credit Suisse first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
- Credit Suisse's Endocyte, Inc. Common Stock position peaked at $4.59M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Credit Suisse's 13F filing for Q4 2018, filed 13 Feb 2019.